Proactol is a 100% natural diet pill, clincally proven to help dieters lose weight without side effects. Proactol stops users from absorbing up to 28% of their fat intake from food.





ProShape RX taken which every meal helps dieters lose weight quickly. ProShape RX decreases food cravings, helps prevent fat storage and may also help increase energy levels.





Zotrim, taken 15 minutes before meals, will help dieters eat less. Zotrim will also decrease in-between meal cravings and may also help increase energy levels and boost metabolism.




Acomplia is a weight loss drug designed to aid individuals struggling with obesity. Acomplia is the first drug in a new type of weight-loss class known as “Cannabinoid-1 Receptor Blockers.” When taken as directed, Acomplia essentially blocks receptors in the brain in order to decrease appetite and control cravings. With this support, consumers are able to lose weight more effectively.
As Acomplia is classified as a “Cannabinoid-1 Receptor Blocker,” or CB1, it works by selectively blocking CB1 receptors in the brain and in peripheral organs. Once these CB1 receptors are blocked, Acomplia works by actively decreasing the over-activity of body systems that control energy balance, fat storage, metabolism, and weight. Most Acomplia users experience significant weight loss in the first 9 months of use, and most consumers report that the weight loss remained stable for two years after taking the drug.
Individuals interested in taking Acomplia must first meet with a physician, as this weight loss drug is only available by prescription. To be approved for Acomplia, individuals must have a Body Mass Index greater than 30. While Acomplia is primarily intended to help individuals succeed with weight loss, this drug is also used to treat conditions such as:
In addition to providing consumers with weight loss benefits, Acomplia has also been utilized to support individuals who are struggling to quit smoking. A one-year study of Acomplia revealed that over 6,500 individuals were able to quit smoking while taking this drug.
While Acomplia has been approved by the European Union since 2006, the United States Food and Drug Administration has not yet approved this drug. Furthermore, some users of Acomplia report experiences of negative side effects such as:
Clinical trials and studies have been conducted in over 6,800 consumers of Acomplia. All trial members were considered to be obese or overweight, and also suffered from additional conditions such as hypertension or dyslipidaemia. In these students, approximately 80% were women, and 20% were men. Over the course of a year, the average Acomplia consumer lost almost 14.5 pounds, compared to individuals who only lost approximately 3.5 pounds while taking a placebo.
Overall, the studies report: